Does the DEA require witnessed waste of controlled substances in a surgery center?

Not for the leftover in the syringe at the end of a case. Federal rules require that waste to be recorded, but they do not impose a two-person witness on it. 21 CFR 1304.21(e) says the destruction of a controlled substance dispensed for immediate administration at your registered location, when it is not fully exhausted, is recorded under 21 CFR 1304.22(c) and need not be maintained on a DEA Form 41. The two-employee witness rule at 21 CFR 1317.95(d) attaches to on-site destruction of stock the center still holds, which is a different record. The witness requirement on procedural waste comes from state rules, accreditation standards and your own facility policy, and it varies from state to state. Knowing which document requires what is what lets you write a waste policy you can defend.

Which waste are we talking about, and which are we not?

Two different acts get called waste, and most arguments about the rule are two people talking about two different acts.

Procedural waste. A drug was drawn and given to a patient at your registered location, and some of it remains. The regulation is concrete: some of the substance remains in a vial, tube or syringe after administration but cannot or may not be further utilized (21 CFR 1304.21(e)). That leftover is recorded as part of the dispensing and administration record under 21 CFR 1304.22(c), which requires the number of units or volume, to whom, the date, and the name or initials of the individual who dispensed or administered it. No Form 41.

Destruction of stock you still hold. An expired vial, a damaged one, an unopened container that came back from a case and is not going back into use. When that stock is destroyed on site, two employees handle or observe the handling of the substance until it is rendered non-retrievable, and two employees personally witness the destruction (21 CFR 1317.95(d)). Non-retrievable is defined at 21 CFR 1300.05: a condition in which the substance has been permanently altered by irreversible means and is unavailable and unusable for all practical purposes. The destruction is recorded on a DEA Form 41, complete and accurate, including the name and signature of the two employees who witnessed it (21 CFR 1304.21(e)).

Two acts, two records, two rules. The two-person requirement sits on the second one. The disposal rules reach a controlled substance in a registrant's inventory (21 CFR 1317.05(a)), which a leftover already dispensed for immediate administration is not. Waste that never ties to a patient at all, a spill, a broken vial, a syringe drawn for a case that was cancelled, is not procedural waste either. It belongs on the destruction side, handled as stock, and DEA guidance points to the Form 41, with two signatures, for a spill or breakage that cannot be recovered.

Why is a DEA witness requirement on procedural waste so widely believed?

Three reasons, and none of them is carelessness.

The first is that the two-employee rule exists, in the same title, about the same drugs, using the word destruction. Anyone who learned it once and never read the exception at the end of 21 CFR 1304.21(e) would carry it across.

The second is that it is often true in practice, just not federally. Your state may require it, your accreditor may require it, and your own policy very likely does. A nurse told on the first day of orientation that waste is witnessed, every time, was told something accurate about the job.

The third is that the correct answer can read, at first glance, like permission to stop witnessing waste. It is not, and dropping the witness on that reading would remove the center's clearest control against diversion and put it out of step with the state rules, accreditation standards and its own policy that still require one. The point of getting the rule right is not to do less. It is to know which authority will ask.

What does your state add?

Federal law is the floor, and many states sit above it. Some address waste through board of pharmacy rules, some through facility licensure, and some not directly at all. If your organization operates centers in more than one state, it is running more than one rule. Your state's current text is the document to read, rather than the summary your policy was first written from.

What does your accreditor add?

Accreditation standards are often what drives a center's waste policy, and they can be more specific than federal law about counting and tracking.

If your center is Quad A accredited, the witness requirement is explicit. Standard 6-D-3 of its Medicare ASC Accreditation Standards Manual v9.1 requires all controlled substance transactions, including daily counts and wastes, to be verified by two licensed members of the team, with one narrow allowance: a facility that stocks only Schedule IV and V substances may use one licensed and one authorized member. The same manual sets the form of the record itself, a sequentially numbered bound journal or a tamper-proof, secure computer record (6-D-2), keeps receipt and disposition records for a minimum of three years, a year beyond the federal two (6-D-4), and reaches the drugs a contracted anesthesia group brings in, which the facility must ensure comply with all QUAD A standards and DEA regulations (6-D-5).

If you are accredited by another organization, its standards manual is the document to read. Many accreditors' manuals are not public, so ask your own accreditor, in writing, what it requires for waste.

Why is the witness the step most likely to slip?

The case ends. There is drug left in the syringe. The patient is moving to recovery, the room is turning over, the next patient is in pre-op, and the nurse who would witness is busy with the handoff.

When the sequence is left to the room, the waste happens first, the paper waits for a gap, and the co-signature is collected after that, sometimes at the end of the day, sometimes from someone who was told about the waste rather than someone who watched it. Nobody in that room is doing anything wrong on purpose. It is the sequence, not the people, that writes the record from memory, and a record written from memory cannot answer a question three months later. A waste policy is written for exactly these ten minutes.

What should your own waste policy say?

If federal law leaves the witness to you, your policy is the rule, and a vague policy is worse than a strict one. Name these:

• What counts as witnessing. Watching the drug leave the syringe, or being told afterward that it happened. Only the first lets the witness say what they saw. Write down which you mean.
• Who may witness, by role, including whether the witness must be licensed and whether the person who signed the drug out may witness its waste.
• When the witnessed co-signature is captured. At the moment of waste, or later, and if later, the limit.
• What happens when no second person is free, whether the day is lightly staffed or busy enough that every hand is occupied. The workable practice is the one your policy probably already requires: hold the waste until a witness is available rather than wasting unwitnessed and signing from memory at the end of the day.
• Where held waste waits. A syringe held for a witness is labeled and locked away, never kept in a pocket, and the policy says for how long.
• What is recorded either way, the federal floor: units or volume, to whom, the date, and the name or initials of the individual who administered (21 CFR 1304.22(c)).
• Where destruction of held stock is handled instead, with the Form 41 and the two witnesses, so nobody applies the procedural-waste rule to an expired vial.
• Which state rule and which accreditation standard the policy is written to, by citation, so the next person to revise it knows what it answered to.

This article describes federal requirements in general terms. It is general information, not legal advice. Countra and Autonomous Healthcare, Inc. are not affiliated with, endorsed by, or acting on behalf of the Drug Enforcement Administration, the Centers for Medicare and Medicaid Services, any state board of pharmacy, or any accrediting organization. Confirm every requirement with your own counsel and your state board of pharmacy before you rely on it. Reviewed and current as of October 26, 2026.

Countra does not make a facility DEA compliant, does not file DEA forms, and does not prevent or guarantee the detection of diversion. Compliance and reporting remain the registrant’s responsibility.